Zydus Lifesciences and Torrent Pharmaceuticals have entered a Licensing and Supply Agreement to co-market Zydus’s innovative Semaglutide Injection (15 mg/3 ml) in India. Zydus will manufacture and supply the product, while Torrent will co-market it under the brand name SEMBOLICTM. The partnership leverages Zydus’s development expertise with Torrent’s strong chronic therapy market presence, aiming to expand patient access for Type 2 diabetes mellitus and chronic weight management.
Strategic Co-Marketing Partnership Announced
Zydus Lifesciences Limited (“Zydus”), an innovation-led global life-sciences company, and Torrent Pharmaceuticals Limited (“Torrent Pharma”), a specialty-focused pharmaceutical company, have formalized a Licensing and Supply Agreement. This agreement focuses on the co-marketing of Zydus’s novel Semaglutide Injection within the Indian market, announced on March 18, 2026.
Product Details and Commercialization Rights
Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) delivered via a patient-friendly reusable pen device. This platform supports delivery for all strengths across both its key indications.
- Zydus will market the product under its established brand names: SEMAGLYNTM, MASHEMATM, and ALTERMETM.
- Torrent Pharma has secured semi-exclusive rights to co-market the product in India under its new brand name, SEMBOLICTM.
- As part of the terms, Torrent Pharma will provide Zydus with an upfront licensing fee.
Therapeutic Focus and Shared Objective
The partnership is specifically aimed at expanding patient access to advanced GLP-1 therapies for metabolic disorders. The core indications covered by the agreement are:
- Treatment of adults with insufficiently controlled type 2 diabetes mellitus, used as an adjunct to diet and exercise.
- Chronic weight management in adults with an initial BMI of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight), provided they have at least one weight-related comorbidity (such as hypertension or dyslipidaemia).
The combined effort seeks to utilize Zydus’s strong manufacturing and development capabilities alongside Torrent Pharma’s extensive field force and deep market expertise across India’s chronic therapy segments. Torrent Pharma is noted for having annual revenues exceeding Rs 11,500 crores and significant presence across therapeutic areas like Cardiovascular and CNS.
Source: BSE
